Find out more about our membership benefits. You need to be a member to download PDF's. Toggle navigation. This website is intended for UK healthcare professionals only Log in Register. Leave a Reply Cancel reply You must be logged in to post a comment. Calorie reduction key to weight loss with heart healthy diets. Alimta approved in Europe as maintenance therapy Lilly received even more good news, this time from European regulators who have expanded approval of Alimta pemetrexed to include maintenance treatment of patients with locally advanced or metastatic nonsquamous, non-small-cell lung cancer whose disease has not progressed immediately following platinum-based chemotherapy.
The data showed that patients with certain subtypes of NSCLC who received Alimta plus best supportive care survived for The news comes less than a week after the FDA granted a similar approval. Free news subscriptions Free RSS feeds.
Prasugrel approval from FDA comes with boxed warning 13th July FDA urged to halt review on prasugrel over safety issues.
Get the latest pharma news delivered to your inbox. After taking into account the higher bleeding rates, the net clinical benefit still favored prasugrel use compared with clopidogrel. Prasugrel was approved for use in Europe by the European Commission in February , and is currently available in the UK. In July , the US Food and Drug Administration FDA approved the use of prasugrel for the reduction of thrombotic cardiovascular events including stent thrombosis in patients with acute coronary syndrome who are to be managed with PCI.
Abstract Prasugrel is a new P2Y 12 receptor antagonist that has been investigated for the treatment of atherothrombosis in patients with cardiovascular disease undergoing percutaneous coronary intervention PCI.
0コメント